D. Robertson

发表

Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial

F. Breedveld, P. Emery, P. Durez, 2008, The Lancet.

Efficacy and safety of continuous versus paused etanercept treatment in patients with moderate-to-severe psoriasis over 54 weeks: the CRYSTEL study

J. Ortonne, C. Griffiths, E. Dauden, 2008 .

The efficacy and safety of etanercept when used with as-needed adjunctive topical therapy in a randomised, double-blind study in subjects with moderate-to-severe psoriasis (the PRISTINE trial)

L. Puig, T. Tsai, R. Pedersen, 2013, The Journal of dermatological treatment.

Sustained improvement in joint pain and nail symptoms with etanercept therapy in patients with moderate‐to‐severe psoriasis

J. Lambert, T. Luger, J. Barker, 2009, Journal of the European Academy of Dermatology and Venereology : JEADV.

Improvements in patient‐reported outcomes in moderate‐to‐severe psoriasis patients receiving continuous or paused etanercept treatment over 54 weeks: the CRYSTEL study

J. Ortonne, K. Kragballe, E. Dauden, 2009, Journal of the European Academy of Dermatology and Venereology : JEADV.

The Challenge of Managing Psoriasis: Unmet Medical Needs and Stakeholder Perspectives.

A. Gottlieb, S. Feldman, M. Kaur, 2016, American health & drug benefits.

Randomized comparison of etanercept with usual therapy in an Asian population with active rheumatoid arthritis: the APPEAL trial

H. Nab, A. Koenig, B. Freundlich, 2012, International journal of rheumatic diseases.

Utility of the PASE questionnaire, psoriatic arthritis (PsA) prevalence and PsA improvement with anti-TNF therapy: results from the PRISTINE trial

A. Qureshi, A. Koenig, R. Pedersen, 2014, The Journal of dermatological treatment.

Improvement in aspects of sleep with etanercept and optional adjunctive topical therapy in patients with moderate‐to‐severe psoriasis: results from the PRISTINE trial

R. Pedersen, D. Robertson, R. Boggs, 2014, Journal of the European Academy of Dermatology and Venereology : JEADV.

Combination etanercept and methotrexate provides better disease control in very early (≤4 months) versus early rheumatoid arthritis (>4 months and <2 years): post hoc analyses from the COMET study

P. Emery, B. Combe, T. Kvien, 2012, Annals of the rheumatic diseases.

Inflammatory eye, skin, and bowel disease in spondyloarthritis: genetic, phenotypic, and environmental factors.

L. Bradbury, A. Calin, S. Brophy, 2001, The Journal of rheumatology.

Spondylodiscitis and pseudarthrosis in a patient with enteropathic spondyloarthropathy.

A. Calin, D. Robertson, 1991, Annals of the rheumatic diseases.

Cardiometabolic profile, clinical features, quality of life and treatment outcomes in patients with moderate-to-severe psoriasis and psoriatic arthritis

L. Puig, T. Tsai, A. Koenig, 2015, The Journal of dermatological treatment.

Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial

J. Ortonne, B. Kirkham, W. Sterry, 2010, BMJ : British Medical Journal.

Inhibition of radiographic progression with combination etanercept and methotrexate in patients with moderately active rheumatoid arthritis previously treated with monotherapy

D. M. van der Heijde, G. Burmester, D. Heijde, 2008, Annals of the rheumatic diseases.

Cardiometabolic biomarkers in chronic plaque psoriasis before and after etanercept treatment

A. Koenig, R. Pedersen, D. Robertson, 2014, The Journal of dermatological treatment.

Self‐reported health outcomes in patients with psoriasis and psoriatic arthritis randomized to two etanercept regimens

A. Zbrozek, R. Gniadecki, R. Pedersen, 2012, Journal of the European Academy of Dermatology and Venereology : JEADV.

Patient-reported outcomes improve with etanercept plus methotrexate in active early rheumatoid arthritis and the improvement is strongly associated with remission: the COMET trial

R. Moots, P. Emery, P. Durez, 2009, Annals of the rheumatic diseases.

Patients with moderate‐to‐severe psoriasis recapture clinical response during re‐treatment with etanercept

J. Ortonne, A. Ormerod, A. Taïeb, 2009, The British journal of dermatology.

Two-year clinical and radiographic results with combination etanercept-methotrexate therapy versus monotherapy in early rheumatoid arthritis: a two-year, double-blind, randomized study.

M. Dougados, F. Breedveld, D. M. van der Heijde, 2010, Arthritis and rheumatism.

Long-term, continuous dosing of etanercept in patients with plaque psoriasis

K. Papp, G. Jemec, G. Krueger, 2011 .

monotherapy patients with moderately active rheumatoid combination etanercept and methotrexate in Inhibition of radiographic progression with

G. Burmester, D. Heijde, C. Codreanu, 2009 .

Combination of skin, joint and quality of life outcomes with etanercept in psoriasis and psoriatic arthritis in the PRESTA trial

O. FitzGerald, R. Pedersen, B. Freundlich, 2011, Journal of the European Academy of Dermatology and Venereology : JEADV.

Combination etanercept and methotrexate provides better disease control in very early (≤4 months) versus early rheumatoid arthritis (>4 months and <2 years): post hoc analyses from the COMET study

P. Emery, B. Combe, T. Kvien, 2012, Annals of the rheumatic diseases.